4D Molecular Therapeutics (FDMT) Receivables - Net (2019 - 2021)

4D Molecular Therapeutics (FDMT) has reported Receivables - Net for 3 consecutive years, with $47000.0 the latest figure, recorded in Q4 2021.

• In Q4 2021, Receivables - Net fell 95.73% year-over-year to $47000.0; the TTM figure through Dec 2021 stood at $47000.0 (down 95.73% YoY), while the FY2021 annual figure was $47000.0, down 96.84% from the prior year.
• Receivables - Net slipped to $47000.0 in Q4 2021 per FDMT's latest filing, from $800000.0 in the prior quarter.
• Across five years, Receivables - Net topped out at $1.2 million in Q2 2021 and bottomed at $47000.0 in Q4 2021.
• Historically, Receivables - Net has averaged $749400.0 across 3 years, with a median of $800000.0 in 2021.
• Annual changes were most pronounced in 2020 — Receivables - Net surged 83.33% — and 2021, when it slumped 95.73%.
• 4D Molecular Therapeutics' Receivables - Net stood at $600000.0 in 2019, then surged by 83.33% to $1.1 million in 2020, then plunged by 95.73% to $47000.0 in 2021.
• Business Quant data shows FDMT's Receivables - Net at $47000.0 in Q4 2021, $800000.0 in Q3 2021, and $1.2 million in Q2 2021.